alpha-Yohimbine

CAS: 131-03-3

Ref. 3D-FY145483

Información del producto

• Nombre: alpha-Yohimbine
• Sinónimos: (-)-Rauwolscine, (16Beta,17Alpha,20Alpha)-17-Hydroxy-16-(Methoxycarbonyl)Yohimban-4-Ium, 20α-Yohimban-16β-carboxylic acid, 17α-hydroxy-, methyl ester, Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv., Corynanthidine, Isoyohimbine, Mesoyohimbine, Methyl (16Beta,17Alpha,20Alpha)-17-Hydroxyyohimban-16-Carboxylate, Methyl (16Beta,17Alpha,20Alpha)-17-Hydroxyyohimban-16-Carboxylate Hydrochloride (1:1), Methyl (16Beta,20Alpha)-17-Hydroxyyohimban-16-Carboxylate, Methyl (17Alpha,20Alpha)-17-Hydroxyyohimban-16-Carboxylate Hydrochloride, Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16β,17α,20α)-, meso-Yohimbine, α-Yohimbine

Descripción

Alpha-yohimbine is an alpha 2 adrenergic receptor antagonist that has been shown to be a potent competitive antagonist at the 5-HT receptor. It has also been shown to have low potency as an α7 nicotinic acetylcholine receptor antagonist and to inhibit locomotor activity in vivo. In humans, alpha-yohimbine increases serum catecholamine levels, but does not affect blood pressure or heart rate. Alpha-yohimbine has been shown to produce a dose-dependent inhibition of erythrocyte aggregation in vitro, and inhibits platelet aggregation in vitro and in vivo. Alpha-yohimbine also inhibits human platelet aggregation induced by collagen or thrombin. Alpha yohimbine is a competitive antagonist of serotonin at the 5HT receptor, but it also has low potency as an α7 nicotinic acetylcholine receptor antagonist and it inhibits locomotor activity in vivo. In humans, alpha-yohimb

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 354.44 g/mol
• Fórmula: C₂₁H₂₆N₂O₃
• Pureza: Min. 98 Area-%
• Color/Forma: Powder
• InChI: InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15+,17+,18+,19+/m1/s1
• Clave InChI: InChIKey=BLGXFZZNTVWLAY-DIRVCLHFSA-N
• SMILES: COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21